Publications

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales. Lead author: M Castanheira, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #2164

Oritavancin Activity Against Gram-positive Isolates Responsible for Intra-Abdominal Infections in Europe and Surrounding Regions During 2015-2019. Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #466

Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa from Patients in ICU of US Medical Centres in 2021. Lead author: HS Sader, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Susceptibility of Enterobacterales Causing Infections in Intensive Care Unit Patients: The Role of New β-Lactamase Inhibitor Combinations. Lead author: CG Carvalhaes, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Activity of Aztreonam-avibactam and Comparator Agents against Ceftazidime-avibactam-resistant Enterobacterales (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #381

Dalbavancin Activity against Bacterial Isolates from Pediatric Patients: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program for the United States and Europe (2019-2021). Lead author: HS Sader presented at St Jude/PIDS Pediatric Infectious Diseases Research Conference, March 3-5, 2022. Virtual conference

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). by Sader HS, Mendes RE, Arends SJR, Carvalhaes CG and Castanheira M. published in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41 (3): 477-487

Activity of the novel aminomethylcycline KBP-7072 and comparators against 1,057 geographically diverse recent clinical isolates from the SENTRY Surveillance Program, 2019. by Huband MD, Thompson JD, Gurung ND, Liu Q, Li L, Zhang J, Streit JM and Castanheira M. published in Antimicrob. Agents Chemother. 2022; 66 (1): e0139721

Activity of oritavancin against Gram-positive pathogens causing bloodstream infections in the United States over 10 Years: Focus on drug-resistant enterococcal subsets (2010-2019). by Carvalhaes CG, Sader HS, Streit JM, Castanheira M and Mendes RE. published in Antimicrob. Agents Chemother. 2022; 66 (2): e0166721

Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. by Sader HS, Carvalhaes CG, Mendes RE and Castanheira M. published in Int. J. Infect. Dis. 2022; 116: 306-312

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. by Sader HS, Castanheira M, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 113: 279-281

Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018-2020). by Sader HS, Mendes RE, Streit JM, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 2022; 102 (1): 115557

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Infective Endocarditis from the United States and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program, Lead author: HS Sader. Presented at CHEST 2021 Annual Meeting, October 17-20, Virtual and Orlando, FL
Poster #36440

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. by Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS and Castanheira M published in J. Antimicrob. Chemother. 2021; 76 (11): 2833-2838

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. by Sader HS, Mendes RE, Doyle TB, Davis AP and Castanheira M. JAC Antimicrob. Resist. 2021; 3 (3): dlab136

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. by Sader HS, Duncan LR, Doyle TB and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (3): dlab126

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases. Lead author: HS SAder presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia. Lead author: H Sader presented at 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), September 9-10, 2021, Virtual Conference
Poster #0323

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates. Lead author: SJR Arends presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the Unites States. Lead author: RE Mendes presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western Europe and Eastern Europe: Results from the SENTRY Program (2018-2020). Lead author: H Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #718

Antimicrobial Activities of Cefepime, Meropenem, Aztreonam, and Piperacillin Combined with Nacubactam against Molecularly Characterized Enterobacterales Collected Worldwide. Lead author: HS Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #893

Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1047

Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1048

Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1626

Evaluation of Pleuromutilins Resistance Mechanisms Among Surveillance Clinical Isolates: Results from the Worldwide Surveillance Program for Lefamulin in 2019. Lead author: RE Mendes, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2146

Activity of Cefiderocol and Comparators against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1606

Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019). by Carvalhaes CG, Sader HS, Rhomberg PR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 92-100

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U. S. gram-negative bacterial surveillance isolates (2012-2018). by Shortridge D, Carvalhaes CG, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2021; 100 (1): 11530

Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. by Sader HS, Carvalhaes CG, Streit JM, Arends SJR and Mendes RE. published in J Glob Antimicrob Resist. 2021; 24: 48-52

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). by Sader HS, Carvalhaes CG and Mendes RE. published in Int. J. Infect. Dis. 2021; 102: 524-528

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): Therapeutic options for multidrug-resistant bacteria. by Sader HS, Castanheira M, Streit JM, Carvalhaes CG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115108

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead Author: Lalitagauri Deshpande. Presented at IDWeek2020.

Poster #1589

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. Lead Author: Helio Sader. Presented at IDWeek 2020.

Poster #1449

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019). Lead Author: Helio Sader. Presented at IDWeek 2020. 

Presentation #37

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019. Lead Author: SJ Ryan Arends. Presented at IDWEEK 2020.

Poster #1262

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #327

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019. Lead author: HS Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1261

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1629